reason
updat
latin
american
thorac
societi
alat
recommend
communityacquir
pneumonia
explain
preambl
updat
recommend
infecti
exacerb
chronic
obstruct
pulmonari
diseas
copd
addit
new
inform
present
text
includ
origin
recommend
make
unnecessari
refer
previou
version
communityacquir
pneumonia
cap
infect
compromis
lung
parenchyma
caus
microorgan
acquir
patient
hospit
environ
sever
diseas
variabl
healthi
individu
cap
mild
may
even
confus
cold
bronchiti
nonrespiratori
infect
also
seriou
lifethreaten
ill
requir
admiss
intens
care
unit
epidemiolog
treatment
cap
chang
consider
recent
year
isol
new
pathogen
emerg
microorgan
develop
resist
tradit
antimicrobi
agent
thank
continu
research
new
antibiot
agent
use
treatment
cap
develop
develop
made
necessari
public
revis
guidelin
manag
common
potenti
seriou
condit
evidencebas
approach
use
draw
recommend
review
relev
studi
publish
support
evid
classifi
level
level
evid
base
random
control
clinic
trial
level
ii
evid
base
welldesign
control
trial
without
random
includ
cohort
studi
case
seri
case
control
studi
level
iii
evid
base
case
report
andor
expert
opinion
treatment
recommend
base
data
concern
suscept
absenc
clinic
observ
evid
classifi
level
iii
object
complementari
method
use
diagnos
cap
follow
ascertain
whether
degre
lung
parenchyma
affect
chest
radiograph
b
identifi
etiolog
agent
microbiolog
serolog
test
c
assess
patient
overal
condit
standard
laboratori
workup
number
type
investig
undertaken
depend
serious
patient
condit
limit
treatment
set
may
sometim
difficult
obtain
chest
radiograph
certain
care
situat
nonetheless
import
stress
least
posteroanterior
radiograph
obtain
diagnosi
cap
addit
make
possibl
firm
diagnosi
pneumonia
chest
radiographi
reveal
extens
diseas
prognost
factor
detect
associ
complic
parapneumon
effus
abscess
cavit
neoplasm
presenc
chronic
lung
injuri
bacteriolog
examin
sputum
includ
gram
stain
cultur
antibiogram
sputum
sampl
use
good
qualiti
except
presenc
inflammatori
reaction
sampl
contamin
oropharyng
flora
inflammatori
reaction
indic
microscop
studi
presenc
squamou
cell
abund
neutrophil
fewer
squamou
cell
special
articl
recommend
communityacquir
pneumonia
neutrophil
per
power
field
accept
limit
valid
sputum
cultur
diminish
substanti
patient
receiv
prior
antibiot
treatment
spite
limit
direct
examin
sputum
use
orient
initi
treatment
level
iii
evid
addit
techniqu
use
sputum
play
valuabl
role
detect
acidalcohol
resist
bacilli
legionella
pneumophila
fungi
pneumocysti
carinii
virus
sputum
cultur
reveal
etiolog
mani
case
howev
sputum
sampl
often
use
specimen
purpos
cultur
result
never
avail
decis
taken
regard
initi
treatment
current
practic
import
sputum
cultur
due
fact
use
document
sensit
differ
pathogen
antibiot
level
iii
evid
sensit
blood
cultur
isol
pathogen
cap
rang
depend
sever
patient
clinic
condit
pleural
fluid
cultur
blood
cultur
use
confirm
etiolog
highli
specif
presenc
pathogen
specimen
gener
consid
constitut
definit
proof
microorgan
isol
caus
agent
cap
blood
cultur
perform
patient
come
emerg
depart
hospit
suspect
infect
microorgan
resist
standard
antibiot
invas
techniqu
reach
bacteriolog
diagnosi
necessari
patient
commonli
use
invas
procedur
involv
bronchoscopi
includ
bronchoalveolar
lavag
protect
specimen
brush
relat
techniqu
lung
biopsi
techniqu
use
immunodepress
highrisk
patient
admit
intens
care
unit
patient
respond
convent
treatment
whose
condit
deterior
clinic
radiograph
serolog
studi
use
diagnosi
certain
type
pneumonia
caus
follow
pathogen
virus
gener
mycoplasma
pneumonia
chlamydia
psittaci
chlamydia
pneumonia
l
pneumophila
coxiella
burnetii
leptospira
interrogan
fungi
hantaviru
howev
use
identifi
caus
retrospect
detect
urinari
antigen
streptococcu
pneumonia
l
pneumophila
use
obtain
quick
etiolog
diagnosi
moreov
highli
reliabl
techniqu
method
yet
wide
use
includ
polymeras
chain
reaction
approv
american
food
drug
administr
detect
mycobacterium
tuberculosi
respiratori
pathogen
tabl
list
diagnost
studi
recommend
cap
patient
accord
sever
ill
basic
laboratori
workup
includ
complet
blood
count
test
urea
glucos
complementari
test
electrophoresi
liver
function
may
also
order
laboratori
test
littl
valu
determin
etiolog
cap
help
determin
prognosi
result
may
affect
decis
hospit
patient
complementari
test
perform
patient
risk
factor
level
ii
evid
blood
gase
analyz
patient
requir
intens
care
may
also
requir
assess
less
sever
ill
inpati
cap
common
potenti
seriou
infect
associ
signific
morbid
annual
incid
cap
among
adult
case
per
popul
incid
higher
among
male
among
young
old
data
incid
difficult
obtain
differ
diagnost
criteria
use
cap
report
diseas
mani
case
report
record
estim
peopl
per
gener
popul
per
age
group
hospit
everi
year
unit
state
america
due
cap
review
popul
studi
indic
overal
rate
hospit
due
cap
patient
requir
care
intens
care
unit
mortal
among
patient
cap
import
patient
without
risk
factor
minimum
option
posteroanterior
chest
radiograph
maximum
option
posteroanterior
later
chest
radiograph
white
blood
cell
differenti
count
bacteriolog
examin
sputum
issu
among
outpati
cap
mortal
recent
metaanalysi
inpati
cap
mortal
overal
among
elderli
among
patient
bacterem
cap
among
patient
requir
intens
care
overal
mortal
chile
pneumonia
lead
caus
death
specif
diagnosi
adult
popul
ahead
acut
myocardi
infarct
cerebrovascular
diseas
accord
chilean
ministri
health
chilean
popul
mortal
hospit
rate
relat
cap
higher
among
young
elderli
similar
situat
report
countri
accord
recent
prospect
studi
immunocompet
adult
patient
hospit
cap
inhospit
mortal
around
overal
among
patient
treat
gener
ward
among
need
intens
care
brazil
cap
fourth
lead
caus
death
common
among
individu
age
report
ministri
health
year
variat
observ
mortal
rate
depend
etiolog
also
import
factor
mortal
vari
maximum
case
cap
caus
pseudomona
minimum
case
caus
enter
bacteria
staphylococcu
aureu
infect
mix
etiolog
mortal
rate
cap
caus
l
pneumophila
pneumonia
case
attribut
virus
atyp
pathogen
mortal
rate
make
cap
fifth
lead
caus
death
industri
countri
cardiovascular
neoplast
cerebrovascular
diseas
copd
cap
also
import
caus
morbid
give
rise
persist
symptom
lead
absente
workplac
recent
popul
studi
although
symptom
disappear
mean
day
diagnosi
mean
time
elaps
return
normal
activ
day
radiograph
resolut
occur
within
day
nearli
patient
howev
among
comorbid
patient
elderli
symptom
attribut
respiratori
infect
often
persist
month
episod
level
ii
evid
light
high
frequenc
cap
clinic
social
repercuss
diseas
creation
public
guidelin
aim
improv
care
affect
patient
fulli
justifi
consid
etiolog
cap
must
take
account
limit
diagnost
test
test
shortcom
evid
studi
report
etiolog
unknown
patient
evid
case
etiolog
agent
identifi
caus
pathogen
pneumonia
level
ii
evid
guidelin
diagnosi
manag
cap
publish
recent
year
base
factor
influenc
etiolog
diseas
need
hospit
sever
ill
patient
age
comorbid
cap
patient
treat
outpati
rel
studi
focus
etiolog
cap
howev
studi
serolog
techniqu
use
other
diagnosi
cap
case
base
clinic
criteria
without
radiograph
confirm
final
studi
percentag
case
etiolog
unknown
high
without
lose
sight
limit
may
conclud
pneumococcu
account
case
haemophilu
influenza
aureu
around
pneumonia
remain
case
pneumonia
undetermin
origin
level
ii
evid
incid
pneumonia
vari
accord
epidem
wave
least
northern
europ
occur
everi
year
sporad
case
found
outsid
epidem
moreov
pneumonia
caus
mycoplasma
common
younger
peopl
therefor
vari
frequenc
depend
demograph
characterist
seri
patient
cap
must
hospit
account
case
variou
prospect
studi
literatur
reveal
pneumonia
caus
pathogen
case
h
influenza
also
frequent
involv
caus
pathogen
gram
neg
bacilli
aureu
respiratori
virus
less
common
level
ii
evid
proport
patient
infect
one
pathogen
time
gener
combin
classic
bacteria
atyp
bacteria
virus
vari
one
studi
anoth
percentag
rang
studi
nearli
other
find
highlight
need
prescrib
broadspectrum
empir
treatment
hospit
patient
cap
level
iii
evid
intens
care
requir
patient
cap
may
repres
patient
admit
intens
care
unit
gener
etiolog
sever
case
pneumonia
similar
moder
case
pneumonia
still
common
caus
pathogen
howev
number
case
attribut
h
influenza
greater
group
make
second
lead
caus
recent
studi
gram
neg
bacilli
associ
cap
patient
chronic
underli
diseas
copd
pseudomona
aeruginosa
found
patient
structur
abnorm
lung
level
iii
evid
frequenc
pneumonia
caus
call
atyp
organ
vari
consider
one
studi
anoth
rate
vari
mainli
due
involv
l
pneumophila
pneumonia
found
common
l
pneumophila
caus
agent
pneumonia
third
lead
caus
recent
studi
pneumonia
continu
frequent
caus
sever
cap
l
pneumophila
respons
case
one
possibl
explan
find
also
report
author
could
increas
use
macrolid
probabl
reduc
number
seriou
case
cap
caus
l
pneumophila
level
iii
evid
cap
caus
l
pneumophila
common
latin
america
incid
undetermin
although
gener
found
sporad
recent
studi
carri
argentina
pathogen
found
cap
patient
two
patient
becom
infect
spain
lead
us
suspect
pathogen
pneumonia
peopl
travel
chile
cabello
et
al
recent
describ
seriou
pneumonia
caus
l
pneumophila
patient
recent
abroad
approxim
adult
popul
chile
serum
antibodi
l
pneumophila
final
sever
viral
pneumonia
gener
rare
analysi
pathogen
caus
cap
elderli
patient
essenti
select
suitabl
empir
treatment
especi
light
fact
death
cap
occur
popul
howev
increas
caprel
morbid
mortal
among
elderli
appear
due
age
rather
interact
divers
immunolog
nutrit
factor
chronic
concomit
diseas
analysi
studi
involv
patient
cap
pneumonia
found
lead
caus
agent
pathogen
gener
consid
respons
case
among
elderli
patient
moreov
number
bacteremia
greater
patient
h
influenza
gram
neg
bacilli
respiratori
virus
aureu
common
among
elderli
younger
individu
hand
lower
percentag
case
cap
among
elderli
caus
pneumonia
atyp
pathogen
level
ii
evid
recent
studi
cap
patient
particular
etiolog
agent
predomin
hand
atyp
pathogen
particular
pneumonia
found
predomin
among
younger
patient
studi
indic
case
cap
elderli
patient
live
nurs
home
special
microbiolog
characterist
point
case
could
consid
compar
nosocomi
pneumonia
sputum
cultur
diagnost
method
use
almost
studi
literatur
etiolog
record
unknown
major
case
pathogen
isol
common
microorgan
pneumonia
h
influenza
aureu
frequenc
gram
neg
bacilli
atyp
pathogen
low
common
concurr
diseas
found
cap
patient
cardiovascular
chronic
neurolog
diseas
copd
howev
airway
often
colon
signific
bacteri
isol
copd
patient
particularli
difficult
establish
etiolog
cap
even
highli
specif
sophist
techniqu
use
spanish
multicent
studi
etiolog
cap
patient
copd
find
larg
differ
copd
patient
rest
popul
hospit
cap
although
highlight
frequenc
c
pneumonia
l
pneumophila
exceed
pneumonia
smoke
alcohol
consumpt
also
associ
presenc
c
pneumonia
hepat
comorbid
alcohol
give
rise
frequent
bacteremia
particular
due
pneumonia
smoke
also
risk
factor
cap
caus
h
influenza
level
ii
evid
alcohol
patient
seem
suffer
frequent
pneumonia
caus
klebsiella
pneumonia
final
pneumonia
caus
p
aeruginosa
common
patient
bronchiectasi
sever
copd
level
iii
evid
particularli
import
note
fact
high
mortal
associ
pathogen
empir
treatment
regimen
usual
use
cap
effect
pseudomona
among
new
caus
agent
cap
emerg
recent
year
c
pneumonia
stand
incid
pathogen
estim
around
patient
seri
report
europ
make
one
common
caus
cap
c
pneumonia
identifi
case
cap
chile
microorgan
usual
found
combin
infect
sole
caus
agent
found
frequent
young
patient
slowli
evolv
symptom
receiv
antimicrobi
treatment
gener
symptom
type
infect
mild
selflimit
howev
recent
studi
c
pneumonia
second
lead
caus
seriou
pneumonia
although
frequent
associ
pathogen
respiratori
virus
becom
increasingli
common
etiolog
agent
cap
popul
studi
case
caus
respiratori
viru
usual
influenza
often
sole
etiolog
agent
patient
requir
hospit
intens
care
recogn
hantaviru
caus
pulmonari
syndrom
associ
high
mortal
rate
throughout
north
south
america
southern
tip
chile
argentina
canada
possibl
emerg
new
cap
etiolog
recent
made
clear
epidem
outbreak
sever
acut
respiratori
syndrom
entiti
atyp
form
pneumonia
caus
highli
contagi
coronaviru
first
appear
rural
region
china
epidem
spread
rapidli
across
south
east
asia
owe
air
travel
produc
sporad
case
europ
countri
america
small
epidem
toronto
canada
mortal
form
cap
risk
factor
unfavor
prognosi
diabet
comorbid
empir
antibiot
treatment
cap
activ
pathogen
commonli
involv
etiolog
particularli
pneumonia
grow
import
past
decad
appear
strain
pneumonia
whose
resist
penicillin
mediat
betalactamas
penicillin
resist
pneumonia
worldwid
problem
becom
seriou
recent
year
usa
number
resist
strain
rose
recent
year
research
chile
studi
strain
pneumonia
isol
respiratori
sampl
taken
adult
hospit
patient
found
strain
resist
penicillin
cefotaxim
erythromycin
find
strain
pneumonia
minimum
inhibitori
concentr
mic
higher
penicillin
result
obtain
anoth
studi
involv
adult
patient
hospit
pneumococc
pneumonia
similar
except
strain
found
resist
erythromycin
strain
isol
either
studi
mic
penicillin
current
definit
resist
stipul
mic
repres
intermedi
level
resist
strain
mic
consid
highli
resist
howev
controversi
continu
regard
clinic
import
vitro
resist
absenc
mening
would
appear
infect
intermedi
resist
respond
high
dose
penicillin
resist
becom
clinic
import
factor
mic
valu
import
rememb
resist
pneumonia
vari
area
area
variat
found
even
within
singl
citi
across
differ
segment
popul
penicillin
resist
also
occasion
impli
crossresist
macrolid
sulfamid
cephalosporin
activ
macrolid
clarithromycin
azithromycin
pneumococcu
often
diminish
penicillin
resist
strain
sever
studi
establish
clinic
featur
often
associ
antibiot
resist
respiratori
pathogen
featur
shown
tabl
effect
cross
resist
seen
antibiot
telithromycin
quinolon
new
fluoroquinolon
activ
pneumococcu
particular
moxifloxacin
gatifloxacin
activ
even
highli
penicillinresist
strain
fluoroquinolon
greater
activ
pneumococcu
use
develop
resist
levofloxacin
treatment
cap
antibiot
describ
result
clinic
failur
import
note
problem
penicillin
resist
grow
continu
recent
year
light
fact
doubt
use
certain
antibiot
tradit
prescrib
cap
betalactam
oral
cephalosporin
macrolid
moreov
cefuroxim
ceftriaxon
betalactam
amoxicillin
without
betalactamas
inhibitor
provid
coverag
atyp
microorgan
high
resist
pneumonia
cotrimoxazol
doxycyclin
latin
america
limit
prescript
antibacteri
agent
telithromycin
foremost
repres
ketolid
good
activ
respiratori
pathogen
includ
strain
pneumococci
resist
betalactam
macrolid
like
new
fluoroquinolon
telithromycin
administ
singl
daili
oral
dose
use
justifi
patient
risk
factor
resist
microorgan
altern
quinolon
patient
mild
moder
cap
level
ii
evid
use
pend
approv
health
also
import
implement
polici
ration
use
antibiot
order
limit
growth
resist
observ
frequenc
resist
pneumonia
variou
antibiot
latin
american
countri
shown
tabl
hospit
admiss
rate
adult
cap
variabl
suggest
standard
protocol
assess
morbid
mortal
risk
cap
patient
thought
physician
often
overestim
risk
morbid
death
patient
cap
consequ
hospit
larg
number
lowrisk
patient
object
categor
patient
accord
risk
help
reduc
variabl
improv
decis
hospit
consequ
costeffect
manag
diseas
fine
et
al
develop
use
model
identifi
lowrisk
patient
appli
predict
rule
step
valid
result
model
indic
patient
low
risk
death
treat
outpati
adequ
identifi
assign
differ
risk
group
ii
iii
discrimin
rule
develop
british
thorac
societi
use
identifi
highrisk
patient
rule
confirm
respiratori
rate
per
minut
diastol
pressur
mm
hg
blood
urea
nitrogen
concentr
mgdl
associ
higher
risk
death
subsequ
modif
criteria
ad
mental
confus
predictor
observ
presenc
factor
associ
increas
risk
death
import
clinic
decis
concern
hospit
made
case
case
basi
physician
avoid
treat
patient
risk
outpati
basi
also
import
minim
number
lowrisk
patient
hospit
unnecessarili
base
number
studi
carri
list
drawn
risk
factor
affect
need
hospit
tabl
cap
patient
appropri
clinic
respons
within
day
start
treatment
howev
patient
fail
respond
treatment
case
reconsid
etiolog
evalu
possibl
resist
caus
agent
consid
complic
factor
relat
host
tabl
among
possibl
caus
consid
includ
follow
atyp
respiratori
pathogen
p
carinii
leptospira
hantaviru
tuberculosi
fungi
viral
agent
noninfecti
pulmonari
infiltr
pulmonari
embol
noninfecti
inflammatori
diseas
bronchiol
obliteran
organ
pneumonia
wegen
granulomatosi
lupu
pneumon
eosinophil
pneumonia
form
vascul
neoplasm
candid
process
secondari
drug
consumpt
amiodaron
pulmonari
toxic
diagnost
reevalu
patient
bronchoscopi
use
tool
clarifi
situat
case
level
ii
evid
caus
suspect
pneumonia
respond
treatment
clear
indic
referr
special
unit
assess
mani
case
carri
invas
diagnost
test
anoth
form
inappropri
respons
treatment
late
respons
slow
resolut
take
form
inadequ
radiograph
improv
day
start
treatment
situat
gener
seen
patient
weaken
defens
mechan
exampl
patient
concurr
diseas
diabet
heart
failur
alcohol
cancer
among
other
slow
respons
may
also
occur
case
pneumonia
caus
atyp
microorgan
staphylococci
andor
gram
neg
bacteria
antibiot
treatment
cap
empir
outset
case
accumul
knowledg
etiolog
cap
particular
geograph
area
suscept
pattern
common
pathogen
avail
antibiot
defin
suitabl
choic
treatment
case
pharmacokinet
pharmacodynam
characterist
antibiot
determin
efficaci
respiratori
infect
case
antibiot
timedepend
bactericid
action
minim
moder
postantibiot
effect
betalactam
macrolid
oxazolidinon
use
predictor
therapeut
efficaci
period
time
serum
concentr
higher
mic
follow
variabl
found
associ
antibacteri
efficaci
case
drug
classifi
concentrationdepend
prolong
postantibiot
effect
aminoglycosid
fluoroquinolon
ketolid
area
concentrationtim
curv
antibiot
relat
mic
also
known
area
inhibitori
curv
auic
maximum
concentrationm
ratio
inhibitori
quotient
auic
repres
time
exposur
maximum
concentr
attain
antimicrobi
agent
place
infect
therefor
also
use
predict
effect
timedepend
antibiot
prolong
elimin
halflif
postantibiot
effect
azithromycin
tetracyclin
streptogramin
dose
regimen
ensur
high
level
antibiot
focu
infect
also
area
normal
colon
may
imped
delay
phenomenon
resist
select
result
easili
achiev
antibiot
concentrationdepend
bactericid
effect
prescrib
way
ensur
inhibitori
quotient
auic
greater
except
case
certain
microorgan
pneumococcu
auic
suffici
object
dose
regimen
antibiot
timedepend
bactericid
effect
obtain
serum
concentr
exceed
mic
pathogen
period
dose
guidelin
recommend
seri
option
antibiot
treatment
chosen
basi
patient
characterist
identifi
greater
risk
infect
caus
certain
pathogen
h
influenza
penicillinresist
pneumonia
anaerob
organ
level
ii
iii
evid
tabl
show
treatment
regimen
cap
patient
treat
outpati
basi
regimen
suitabl
empir
treatment
patient
without
risk
factor
penicillinresist
pneumococc
enter
gram
neg
bacteria
level
evid
two
possibl
option
given
amoxicillin
may
also
use
likelihood
typic
pneumonia
high
case
risk
factor
penicillin
resist
pneumonia
macrolid
treatment
choic
fluoroquinolon
telithromycin
tabl
deal
seriou
case
cap
patient
requir
hospit
possibl
etiolog
recommend
antibiot
treatment
regimen
vari
tabl
physician
consid
possibl
infect
anaerob
bacteria
elderli
patient
swallow
problem
low
level
awar
may
aspir
pharyng
gastric
content
intraven
therapi
may
necessari
hospit
patient
owe
excel
pharmacokinet
properti
new
quinolon
oral
administr
may
equal
effect
level
iii
evid
final
patient
requir
intens
care
extrem
serious
condit
treat
use
empir
regimen
shown
tabl
case
patient
categor
accord
whether
risk
cap
caus
p
aeruginosa
risk
factor
cap
caus
pseudomona
follow
prior
histori
pneumonia
caus
pseudomona
signific
bronchiectasi
sever
copd
level
iii
evid
frequent
use
antibiot
dosag
regimen
shown
tabl
durat
treatment
typic
day
howev
shorter
treatment
possibl
day
use
drug
long
half
life
azithromycin
day
new
fluoroquinolon
telithromycin
new
approach
switch
rapidli
intraven
oral
antibiot
switch
therapi
choic
regimen
base
appropri
clinic
assess
understand
pharmacokinet
pharmacodynam
properti
indic
antimicrobi
agent
switch
oral
administr
shown
reduc
length
hospit
stay
cost
effect
option
level
evid
antimicrobi
agent
fluoroquinolon
linezolid
attain
compar
blood
concentr
whether
administ
oral
intraven
level
evid
other
betalactam
attain
lower
concentr
administ
oral
still
provid
adequ
effect
treatment
level
evid
new
treatment
includ
use
longer
interv
short
half
life
drug
short
treatment
day
antimicrobi
drug
azithromycin
telithromycin
new
fluoroquinolon
smoke
increas
risk
cap
consequ
smoker
first
prevent
measur
quit
smoke
level
ii
evid
prevent
measur
vaccin
also
implement
level
ii
evid
influenza
vaccin
particular
interest
administ
everi
year
follow
world
health
organ
recommend
target
strain
specifi
institut
sinc
demonstr
vaccin
also
reduc
infect
lower
airway
administr
pneumococc
vaccin
also
recommend
administ
peopl
year
age
patient
chronic
diseas
increas
suscept
pneumococc
infect
recommend
intern
guidelin
aim
cap
recommend
modifi
local
clinic
practic
direct
ideal
practic
recommend
guidelin
process
implement
guidelin
within
local
area
region
requir
object
met
first
step
creation
local
document
detail
specif
intervent
consid
constitut
ideal
alat
approach
treat
patient
cap
second
step
involv
collect
analyz
data
concern
actual
practic
data
illustr
diverg
exist
actual
ideal
practic
diverg
ideal
practic
analyz
assess
happen
decid
whether
variat
justifi
third
step
includ
implement
local
intervent
aim
reduc
diverg
ideal
practic
final
stage
involv
gather
analyz
data
concern
result
intervent
use
process
possibl
gaug
whether
diverg
ideal
care
minim
elimin
import
document
whether
distanc
actual
practic
ideal
approach
reduc
sinc
would
clearli
demonstr
cap
guidelin
produc
desir
effect
achiev
first
object
expert
team
local
hospit
draw
guidelin
ideal
care
base
care
review
literatur
mere
publish
result
guidelin
may
produc
chang
current
practic
public
accompani
renew
effort
implement
promot
guidelin
use
implement
potenti
obstacl
may
appear
follow
obstacl
may
emerg
implement
second
phase
lack
experi
measur
result
b
insuffici
time
skill
part
person
charg
collect
evalu
data
c
lack
experi
evalu
variat
practic
defin
justif
follow
problem
could
aris
third
phase
lack
personnel
appropri
skill
implement
action
aim
chang
local
practic
b
lack
support
author
implement
action
aim
correct
attitud
final
follow
problem
could
occur
fourth
stage
lack
personnel
collect
quantifi
data
b
lack
inform
requir
assess
variat
practic
time
ultim
aim
cap
guidelin
elimin
differ
actual
practic
ideal
approach
everi
local
hospit
order
achiev
object
physician
health
profession
involv
must
clear
idea
implement
guidelin
correct
problem
applic
cap
common
diseas
especi
among
young
elderli
latin
american
countri
one
lead
caus
hospit
death
adult
emerg
new
caus
microorgan
develop
antibiot
resist
part
common
pathogen
made
necessari
revis
guidelin
deal
infect
pneumococcu
still
microorgan
often
caus
cap
throughout
differ
countri
risk
group
countri
prescript
newli
approv
antibiot
new
quinolon
ketolid
essenti
resist
rate
pneumococcu
penicillin
macrolid
howev
area
resist
rate
still
low
tradit
antibiot
may
still
use
treat
outpati
cap
identif
risk
factor
associ
unfavor
prognosi
infect
resist
atyp
microorgan
improv
empir
treatment
cap
guidelin
detail
princip
risk
factor
describ
literatur
inform
help
choos
appropri
antibiot
regimen
measur
gener
improv
live
condit
access
medic
care
prevent
measur
vaccin
inservic
train
health
care
profession
posit
affect
incid
consequ
cap
